Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

8.260 +0.020 (+0.24%)
Streaming Delayed Price Updated: 3:09 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 351,712
Open 8.200
Bid (Size) 8.240 (1)
Ask (Size) 8.300 (2)
Prev. Close 8.240
Today's Range 8.060 - 8.570
52wk Range 1.730 - 11.41
Shares Outstanding 30,674,855
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study
Via Stocktwits
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire

Performance

YTD
+84.0%
+84.0%
1 Month
+19.4%
+19.4%
3 Month
-10.9%
-10.9%
6 Month
+141.5%
+141.5%
1 Year
+37.9%
+37.9%

More News

Read More
This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
From Sagimet Biosciences Inc.
Via GlobeNewswire
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Tops Q2 EPS Forecast
Via The Motley Fool
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Here are the top movers in Thursday's session.
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
These stocks are moving in today's pre-market session
Via Chartmill
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
The market is filled with gapping stocks in Monday's session.
Via Chartmill

Frequently Asked Questions

Is Sagimet Biosciences Inc. - Series A Common Stock publicly traded?
Yes, Sagimet Biosciences Inc. - Series A Common Stock is publicly traded.
What exchange does Sagimet Biosciences Inc. - Series A Common Stock trade on?
Sagimet Biosciences Inc. - Series A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock?
The ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock is SGMT on the Nasdaq Stock Market
What is the current price of Sagimet Biosciences Inc. - Series A Common Stock?
The current price of Sagimet Biosciences Inc. - Series A Common Stock is 8.260
When was Sagimet Biosciences Inc. - Series A Common Stock last traded?
The last trade of Sagimet Biosciences Inc. - Series A Common Stock was at 10/29/25 03:09 PM ET
What is the market capitalization of Sagimet Biosciences Inc. - Series A Common Stock?
The market capitalization of Sagimet Biosciences Inc. - Series A Common Stock is 253.37M
How many shares of Sagimet Biosciences Inc. - Series A Common Stock are outstanding?
Sagimet Biosciences Inc. - Series A Common Stock has 253M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.